References

References

Abdelrazeq AS, Kelly SM, Lund JN et al. (2005) Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Disease 7: 182–6

European Crohn's and Colitis Organisation (ECCO) (2008) European evidence-based consensus on the management of ulcerative colitis: special situations. Journal of Crohn's and Colitis 2: 63–92

General Medical Council (2013) Prescribing guidance: prescribing unlicenced medicines [online; accessed 14 January 2014]

Gionchetti P, Rizzello F, Venturi A et al. (1999) Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Alimentary Pharmacology and Therapeutics 13: 713–8

Health and Social Care Information Centre (2013) Prescription cost analysis: England 2012 [online; accessed 14 January 2014]

Isaacs KL, Sandler RS, Abreu M et al. (2007) Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflammatory Bowel Diseases 13: 1250–5

National Institute for Health and Clinical Excellence (2011) Colorectal cancer: the diagnosis and management of colorectal cancer. NICE clinical guideline 131

National Institute for Health and Care Excellence (2013) Ulcerative colitis: management in adults, children and young people. NICE clinical guideline 166

NHS Business Services Authority, NHS Prescription Services (2013) NHS electronic drug tariff [online; accessed 7 February 2014 ]

Norgine Limited (2011) Xifaxanta 200mg film-coated tablets: SPC [online; accessed 14 January 2014]

Norgine Limited (2013) Targaxan 550mg film-coated tablets: SPC [online; accessed 14 January 2014]

Shen B, Remzi FH, Lopez AR et al. (2008) Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BioMed Central Gastroenterology 8: 26